Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02628067
Other study ID # 3475-158
Secondary ID 163196MK-3475-15
Status Recruiting
Phase Phase 2
First received
Last updated
Start date December 18, 2015
Est. completion date May 4, 2027

Study information

Verified date May 2024
Source Merck Sharp & Dohme LLC
Contact Toll Free Number
Phone 1-888-577-8839
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).


Recruitment information / eligibility

Status Recruiting
Enrollment 1609
Est. completion date May 4, 2027
Est. primary completion date May 4, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically or cytologically-documented, advanced solid tumor of one of the following types: - Anal Squamous Cell Carcinoma - Biliary Adenocarcinoma (gallbladder or biliary tree (intrahepatic or extrahepatic cholangiocarcinoma) except Ampulla of Vater cancers) - Neuroendocrine Tumors (well- and moderately-differentiated) of the lung, appendix, small intestine, colon, rectum, or pancreas - Endometrial Carcinoma (sarcomas and mesenchymal tumors are excluded) - Cervical Squamous Cell Carcinoma - Vulvar Squamous Cell Carcinoma - Small Cell Lung Carcinoma - Mesothelioma - Thyroid Carcinoma - Salivary Gland Carcinoma (sarcomas and mesenchymal tumors are excluded) - Any advanced solid tumor, with the exception of colorectal carcinoma (CRC), which is Microsatellite Instability (MSI)-High (MSI-H) OR - Any advanced solid tumor (including Colorectal Carcinoma [CRC]) which is Mismatch Repair Deficient (dMMR)/MSI-H in participants from mainland China who are of Chinese descent. (CRC participants will have a histologically proven locally advanced unresectable or metastatic CRC which is dMMR/MSI-H that has received 2 prior lines of therapy) OR - Any advanced solid tumor that has failed at least one line of therapy and is TMB-H (=10 mut/Mb, F1CDx assay), excluding dMMR/MSI-H tumors. Note: For participants to be eligible for enrollment they must have failed at least one line of standard of care systemic therapy (ie, not treatment naïve), with the exception of CRC participants who must have failed at least 2 lines of standard of care systemic therapy, as per CRC specific eligibility criteria. Participants must not have melanoma or NSCLC. - Progression of tumor or intolerance to therapies known to provide clinical benefit. There is no limit to the number of prior treatment regimens - Can supply tumor tissue for study analyses (dependent on tumor type) - Radiologically-measurable disease - Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale within 3 days prior to first dose of pembrolizumab - Life expectancy of at least 3 months - Adequate organ function - Female participants of childbearing potential must be willing to use adequate contraception during the intervention period and for at least the time needed to eliminate each study intervention after the last dose of study intervention. and agrees not to donate eggs (ova, oocytes) to others or freeze/store for her own use for the purpose of reproduction during this period. The length of time required to continue contraception for each study intervention is as follows: MK-3475 (120 days) Exclusion Criteria: - Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study treatment - Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment - Active autoimmune disease that has required systemic treatment in the past 2 years - Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or not recovered from an adverse event caused by mAbs administered more than 4 weeks earlier - Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks of study Day 1 or not recovered from adverse events caused by a previously administered agent - Known additional malignancy within 2 years prior to enrollment with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cancers - Known active central nervous system (CNS) metastases and/or carcinomatous meningitis - Has known glioblastoma multiforme of the brain stem - Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease. - Active infection requiring systemic therapy - Known psychiatric or substance abuse disorders that would interfere with the participant's ability to cooperate with the requirements of the study - Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment - Previously participated in any other pembrolizumab (MK-3475) study, or received prior therapy with an anti-programmed cell death (PD)-1, anti-PD-Ligand 1 (anti-PD-L1), anti-PD-Ligand 2 (anti-PD-L2), or any other immunomodulating mAb or drug specifically targeting T-cell co-stimulation or checkpoint pathways - Known history of Human Immunodeficiency Virus (HIV) - Known active Hepatitis B or C - Received live vaccine within 30 days of planned start of study treatment - Has severe hypersensitivity (=Grade 3) to pembrolizumab and/or any of its excipients - Known history of active tuberculosis (TB, Bacillus tuberculosis) - Has had an allogenic tissue/solid organ transplant.

Study Design


Related Conditions & MeSH terms

  • Advanced Cancer
  • Advanced Solid Tumors
  • Anal Cancer
  • Anal Carcinoma
  • Anus Neoplasms
  • Bile Duct Cancer
  • Bile Duct Neoplasms
  • Biliary Cancer
  • Carcinoid Tumor
  • Carcinoma
  • Cervical Cancer
  • Cervical Carcinoma
  • Cholangiocarcinoma
  • Colorectal Carcinoma
  • Colorectal Neoplasms
  • Endometrial Cancer
  • Endometrial Carcinoma
  • Endometrial Neoplasms
  • Mesothelioma
  • Neoplasms
  • Neuroendocrine Tumor
  • Neuroendocrine Tumors
  • Parotid Gland Cancer
  • Salivary Cancer
  • Salivary Gland Cancer
  • Salivary Gland Carcinoma
  • Salivary Gland Neoplasms
  • Small Cell Lung Cancer (SCLC)
  • Small Cell Lung Carcinoma
  • Thyroid Cancer
  • Thyroid Carcinoma
  • Thyroid Diseases
  • Thyroid Neoplasms
  • Vulvar Cancer
  • Vulvar Carcinoma
  • Vulvar Neoplasms

Intervention

Biological:
pembrolizumab
intravenous infusion
pembrolizumab
intravenous infusion

Locations

Country Name City State
Australia MSD Australia North Ryde
Brazil MSD Brasil Sao Paulo
Canada Merck Canada Kirkland Quebec
Chile Merck Sharp & Dohme (I.A.) Corp. Santiago
Colombia MDS Colombia SAS Bogota
Denmark MSD Denmark Glostrup
France MSD France Paris
Germany MSD Sharp & Dohme GmbH Haar
Israel Merck Sharp & Dohme Co. Ltd. Hod Hasharon
Italy MSD Italia S.r.l. Rome
Korea, Republic of MSD Korea LTD Seoul
Mexico MSD Mexico City
Netherlands Merck Sharp & Dohme BV Haarlem
Norway MSD Norge A/S Drammen
Peru Merck Sharp & Dohme, Peru S.R.L. Lima
Philippines Merck Sharp & Dohme (I.A.) Corporation Makati
Poland MSD Polska Sp. Z o.o. Warsaw
Portugal Merck Sharp & Dohme Lda. Paco D'arcos
Russian Federation Merck Sharp & Dohme IDEA, Inc. Moscow
South Africa MSD (Pty) LTD South Africa Midrand
Spain Merck Sharp and Dohme de Espana S.A. Madrid
Taiwan Merck Sharp & Dohme (I.A.) Corp. Taipei
United States Call for Information (Investigational Site 0008) New Brunswick New Jersey

Sponsors (1)

Lead Sponsor Collaborator
Merck Sharp & Dohme LLC

Countries where clinical trial is conducted

United States,  Australia,  Brazil,  Canada,  Chile,  Colombia,  Denmark,  France,  Germany,  Israel,  Italy,  Korea, Republic of,  Mexico,  Netherlands,  Norway,  Peru,  Philippines,  Poland,  Portugal,  Russian Federation,  South Africa,  Spain,  Taiwan, 

References & Publications (1)

Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, Piha-Paul SA, Doi T, Gao B, Chung HC, Lopez-Martin J, Bang YJ, Frommer RS, Shah M, Ghori R, Joe AK, Pruitt SK, Diaz LA Jr. Efficacy of P — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Objective Response Rate (ORR) ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ at any time during the trial. Responses will be determined by independent central radiologic review, with confirmatory assessment as required per RECIST 1.1. Participants with unknown or missing response information will be treated as non-responders. The percentage of participants who experience a CR or PR based on modified RECIST 1.1 will be presented. Up to approximately 10.5 years
Secondary Duration of Response (DOR) DOR, defined in the subset of participants with a CR or PR, based on RECIST 1.1 as assessed by independent central radiologic review, as the time from first documented evidence of CR or PR until the first documented sign of disease progression or death due to any cause, whichever occurs first. A Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. Participants who are alive, have not progressed, have not initiated new anti-cancer treatment, and have not been determined to be lost to follow-up are considered ongoing responders at the time of analysis. Up to approximately 10.5 years
Secondary Progression Free Survival (PFS) PFS is defined as the time from allocation to the first documented disease progression according to RECIST 1.1 as assessed by independent central radiologic review, or death due to any cause, whichever occurs first. Per RECIST 1.1, progressive disease (PD) is defined as =20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of =5 mm. Note: The appearance of one or more new lesions is also considered PD. If a participant does not have a documented date of progression or death, PFS will be censored at the date of the last adequate assessment. Up to approximately 10.5 years
Secondary Overall Survival (OS) OS is defined as the time from randomization to death due to any cause. OS will be presented. Censoring will be performed using the date of last known contact for those who are alive at the time of analysis. Up to approximately 10.5 years
Secondary Percentage of Participants with Adverse Events (AEs) An adverse event (AE) is defined as any untoward medical occurrence in a study participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this intervention. The percentage of participants with AEs will be reported. Up to approximately 27 months
Secondary Percentage of Participants who Discontinue Study Intervention due to AEs An AE is defined as any untoward medical occurrence in a study participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The percentage of participants who discontinue study intervention due to AEs will be reported. Up to approximately 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT03367871 - Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer Phase 2
Active, not recruiting NCT04537156 - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 3
Recruiting NCT03668639 - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin Phase 2/Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Withdrawn NCT04806945 - A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer Phase 3
Active, not recruiting NCT04185389 - Long-Term Follow-Up of HPV FOCAL Participants
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Completed NCT05120167 - Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy N/A
Recruiting NCT05483491 - KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer Phase 1
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Completed NCT05862844 - Promise Women Project N/A
Recruiting NCT04934982 - Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2) N/A
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT00543543 - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Phase 3
Terminated NCT04864782 - QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer Phase 2/Phase 3
Recruiting NCT04226313 - Self-sampling for Non-attenders to Cervical Cancer Screening N/A